Suzhou Angtop Biopharmaceutical

Angtop Biopharmaceutical is a China-based biotechnology company dedicated to the development of next-generation RNA therapeutics, specifically focusing on small interfering RNA (siRNA) and antisense oligonucleotides (ASO). Founded by industry veterans with extensive experience from leading global RNA companies like Alnylam and Ionis, the company leverages its proprietary delivery platforms to target chronic and rare diseases. Angtop's technology focuses on optimizing the stability and delivery of oligonucleotides to both hepatic and extrahepatic tissues. The company has successfully raised significant venture capital to advance its pipeline of metabolic and cardiovascular candidates toward clinical trials. Their business model centers on internal drug discovery and the potential for strategic partnerships in the RNA medicine space.